Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction
The in vitro research effects of this carrier peptides is to deliver copper to the skin to activate enzymatic wound-healing pathways, while the desired, in vivo, effect is to make the skin more smooth, thick, and firm due to increased collagen production
We typically put our patients on weekly injections for a minimum of 12 weeks, or three months of treatment
NICE guidance (NG28) recommends structured follow-up for patients on GLP-1 therapy, with specific continuation criteria that must be met to justify ongoing treatment
Always speak to your doctor if belching becomes persistent or severe
Store them away from light and moisture and keep out of reach of children